Atossa Therapeutics - ATOS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.50
  • Forecasted Upside: 332.69%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.04
▲ +0.01 (0.97%)

This chart shows the closing price for ATOS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Atossa Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATOS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATOS

Analyst Price Target is $4.50
▲ +332.69% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Atossa Therapeutics in the last 3 months. The average price target is $4.50, with a high forecast of $5.00 and a low forecast of $4.00. The average price target represents a 332.69% upside from the last price of $1.04.

This chart shows the closing price for ATOS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Atossa Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2024HC WainwrightReiterated RatingBuy$4.00Low
1/12/2024Cantor FitzgeraldReiterated RatingOverweightLow
12/18/2023Cantor FitzgeraldReiterated RatingOverweightLow
9/8/2023Cantor FitzgeraldInitiated CoverageOverweight$5.00Low
11/16/2022Ascendiant Capital MarketsLower Target$6.00N/A
8/22/2022Ascendiant Capital MarketsLower Target$7.00Low
9/18/2020Maxim GroupReiterated RatingBuy$8.00Medium
9/17/2020Ascendiant Capital MarketsInitiated CoverageBuy$7.00High
7/31/2020Maxim GroupReiterated RatingBuy$8.00Low
7/17/2020Maxim GroupBoost Target$4.00 ➝ $8.00High
7/16/2020Maxim GroupReiterated RatingPositiveHigh
5/23/2020Maxim GroupInitiated CoverageBuy$4.00Low
4/28/2020Maxim GroupInitiated CoverageBuy$4.00Low
4/17/2020Maxim GroupReiterated RatingBuy$4.00Low
12/18/2019Maxim GroupUpgradeHold ➝ BuyHigh
6/27/2019Maxim GroupDowngradeBuy ➝ HoldLow
3/26/2019Maxim GroupReiterated RatingBuy$9.00High
(Data available from 2/28/2019 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
8/2/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
9/1/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
10/1/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/31/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/30/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/30/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/29/2024
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/28/2024

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Atossa Therapeutics logo
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $1.04
Low: $1.00
High: $1.04

50 Day Range

MA: $0.90
Low: $0.73
High: $1.03

52 Week Range

Now: $1.04
Low: $0.59
High: $1.39

Volume

191,797 shs

Average Volume

402,208 shs

Market Capitalization

$130.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

Frequently Asked Questions

What sell-side analysts currently cover shares of Atossa Therapeutics?

The following Wall Street research analysts have issued stock ratings on Atossa Therapeutics in the last year: Cantor Fitzgerald, HC Wainwright, and StockNews.com.
View the latest analyst ratings for ATOS.

What is the current price target for Atossa Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Atossa Therapeutics in the last year. Their average twelve-month price target is $4.50, suggesting a possible upside of 332.7%. Cantor Fitzgerald has the highest price target set, predicting ATOS will reach $5.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $4.00 for Atossa Therapeutics in the next year.
View the latest price targets for ATOS.

What is the current consensus analyst rating for Atossa Therapeutics?

Atossa Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATOS will outperform the market and that investors should add to their positions of Atossa Therapeutics.
View the latest ratings for ATOS.

What other companies compete with Atossa Therapeutics?

How do I contact Atossa Therapeutics' investor relations team?

Atossa Therapeutics' physical mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company's listed phone number is (206) 588-0256 and its investor relations email address is [email protected]. The official website for Atossa Therapeutics is atossatherapeutics.com. Learn More about contacing Atossa Therapeutics investor relations.